NCT03843632 - Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

June 19, 2020

Study Completion Date

June 19, 2020

Conditions

Varicella

Interventions

BIOLOGICAL

VARIVAX™

VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).

Trial Locations (5)

197022

Research Institute of Children Infections ( Site 5801), Saint Petersburg

197101

SPb Pasteur RI of Epidemiology and Microbiology ( Site 5817), Saint Petersburg

214019

Smolensk State Medical University ( Site 5814), Smolensk

Smolensk State Medical University ( Site 5815), Smolensk

420140

Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 5816), Kazan'

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY